# Endocannabinoid Modulation in Headache: Mechanisms, Models, and Translational Therapies

## TL;DR

The endocannabinoid system plays a key role in headache disorders, and targeting it offers promising new treatment strategies, especially considering sex differences.

## Contribution

The paper highlights the ECS as a novel therapeutic target for headache disorders, emphasizing sex differences and translational strategies.

## Key findings

- ECS dysfunction contributes to central sensitization and reduced descending inhibition in chronic headaches.
- Pharmacological targeting of endocannabinoid degradation consistently reduces headache-like behaviors in preclinical models.
- Sex differences significantly influence ECS signaling and therapeutic responsiveness.

## Abstract

What are the main findings?
The endocannabinoid system (ECS) is a central regulator of neural, vascular, and immune mechanisms driving headache disorders.ECS dysfunction contributes to central sensitization and reduced descending inhibition, particularly in chronic headaches.

The endocannabinoid system (ECS) is a central regulator of neural, vascular, and immune mechanisms driving headache disorders.

ECS dysfunction contributes to central sensitization and reduced descending inhibition, particularly in chronic headaches.

What are the implications of the main findings?
Targeting endocannabinoid hydrolysis and oxygenation shows consistent preclinical efficacy and represents a promising therapeutic strategy.Sex differences significantly influence ECS signaling and therapeutic responsiveness.

Targeting endocannabinoid hydrolysis and oxygenation shows consistent preclinical efficacy and represents a promising therapeutic strategy.

Sex differences significantly influence ECS signaling and therapeutic responsiveness.

Headache disorders, including migraine, tension-type headache, trigeminal autonomic cephalalgias, post-traumatic headache and medication overuse headache, represent a major global health burden and remain difficult to treat despite therapeutic advances. The endocannabinoid system (ECS) has emerged as a key regulator of neural, vascular, and immune processes central to headache pathophysiology. Through coordinated actions of CB1 and CB2 receptors, the endogenous ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes, the ECS modulates trigeminovascular activity, descending pain control, cortical excitability, and neuroimmune sensitization. Preclinical studies demonstrate that ECS activation suppresses trigeminal firing, reduces calcitonin gene-related peptide (CGRP) release, attenuates neurogenic inflammation, stabilizes cortical susceptibility to spreading depression, and limits glial activation following traumatic brain injury. Conversely, ECS dysregulation contributes to central sensitization and impaired descending inhibition underlying medication overuse headache and other headache disorders. Pharmacological strategies targeting endocannabinoid degradation, such as inhibition of FAAH, MAGL, and COX-2, enhance endogenous cannabinoid tone and consistently reduce headache-like behaviors across diverse models. Importantly, sex differences shape ECS function, with females exhibiting distinct hormonal regulation, receptor expression, and glial activation that influence responsiveness to ECS-targeted interventions. Collectively, mechanistic and translational evidence highlights the ECS as a promising therapeutic target across primary and secondary headache disorders. Future clinical studies should incorporate sex-informed designs, integrate biomarkers of trigeminovascular and neuroimmune activity, and evaluate peripherally restricted ECS modulators and cannabinoid-based formulations as candidates for individualized headache therapy.